Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

PMID:
29767677
2.

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.

Xu M, Kallinteris NL, von Hofe E.

Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Review.

PMID:
22386748
3.

Recognition of Ii-Key/MHC class II epitope hybrids derived from proinsulin and GAD peptides by T cells in type 1 diabetes.

Vadacca M, Valorani MG, von Hofe E, Kallinteris NL, Buzzetti R, Pozzilli P.

Horm Metab Res. 2011 Jun;43(7):483-8. doi: 10.1055/s-0031-1275705. Epub 2011 Apr 21.

PMID:
21512962
4.

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.

Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN.

Clin Cancer Res. 2010 Jul 1;16(13):3495-506. doi: 10.1158/1078-0432.CCR-10-0085. Epub 2010 May 13.

5.

A new era in anticancer peptide vaccines.

Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN.

Cancer. 2010 May 1;116(9):2071-80. doi: 10.1002/cncr.24988. Review.

6.

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.

Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN.

Int J Cancer. 2007 Nov 1;121(9):2031-41.

7.

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.

Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M.

Expert Opin Biol Ther. 2006 Dec;6(12):1311-21. Review.

PMID:
17223739
8.

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.

PMID:
16960693
9.

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.

Kallinteris NL, Powell D, Blackwell CE, Kim M, Lu X, Wu S, Humphreys RE, Xu M, von Hofe E.

Front Biosci. 2006 Jan 1;11:46-58. Review.

PMID:
16146713
10.
11.

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.

Wang Y, Xu M, Che M, Von Hofe E, Abbas A, Kallinteris NL, Lu X, Liss ZJ, Forman JD, Hillman GG.

Hum Gene Ther. 2005 Feb;16(2):187-99.

PMID:
15761259
12.

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.

Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M.

Vaccine. 2005 Mar 18;23(17-18):2336-8.

PMID:
15755623
13.

Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.

Xu M, Lu X, Kallinteris NL, Wang Y, Wu S, von Hofe E, Gulfo JV, Humphreys RE, Hillman GG.

Curr Opin Mol Ther. 2004 Apr;6(2):160-5.

PMID:
15195928
14.

Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.

Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, Xu M.

Cancer Treat Rev. 2004 May;30(3):281-90. Review.

PMID:
15059651
15.

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.

Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL.

Cancer Immunol Immunother. 2004 Jun;53(6):490-6. Epub 2004 Jan 22.

PMID:
14740174
16.

Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV.

Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE, Xu M.

Vaccine. 2003 Oct 1;21(27-30):4128-32.

PMID:
14505892
17.

Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.

Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M.

Gene Ther. 2003 Aug;10(17):1512-8.

PMID:
12900767
18.

Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.

Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M.

Cancer Immunol Immunother. 2003 Oct;52(10):592-8. Epub 2003 Jun 19.

PMID:
12827305
19.

Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma.

Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD.

Hum Gene Ther. 2003 May 20;14(8):763-75.

PMID:
12804139

Supplemental Content

Loading ...
Support Center